Literature DB >> 8055235

The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.

V A Luketic1, A J Sanyal.   

Abstract

Cholestasis results from either failure of bile formation or obstruction to bile flow. Liver diseases characterized by chronic cholestasis frequently cause progressive hepatocellular injury, cirrhosis, and death. Recent studies have shown that bile salts have an important role in the genesis and maintenance of liver injury in chronic cholestatic liver diseases. Ursodeoxycholic acid, a unique bile acid, protects the liver from injury by harmful bile acids and has been shown to improve symptoms and to delay the onset of liver failure and complications of cirrhosis. The rationale for its use and the results from clinical trials in chronic cholestasis are reviewed. Recommendations for the use of ursodeoxycholic acid in chronic cholestatic liver diseases are provided.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8055235

Source DB:  PubMed          Journal:  Gastroenterologist        ISSN: 1065-2477


  4 in total

1.  Management Of Primary Sclerosing Cholangitis.

Authors:  Bimaljit S Sandhu; Velimir A Luketic
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-11

Review 2.  [Cholestasis and liver dysfunction in critical care patients].

Authors:  M Kredel; J Brederlau; N Roewer; C Wunder
Journal:  Anaesthesist       Date:  2008-12       Impact factor: 1.041

3.  Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats.

Authors:  Amr A A Mahmoud; Shimaa M Elshazly
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

4.  Ursodeoxycholic Acid Protects Against Arsenic Induced Hepatotoxicity by the Nrf2 Signaling Pathway.

Authors:  Chao Li; Sheng Zhang; Liming Li; Qing Hu; Shen Ji
Journal:  Front Pharmacol       Date:  2020-10-16       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.